Thank you, Chintu, and good morning, everyone.
generation XXXX and value deleveraging. and X with excited the a cash As across I'm are beyond. creation diversification, financial about X pleased extremely our at XXXX all in reminder, and pillars growth, performance pillars Amneal of
in more of new strong complex has diversification, me made remarkable our progress brands and such specialty start expanding of with Let biosimilars. driven cadence as Amneal growth products, new, first areas by AvKARE, where
account of As total account our XX% solid revenue XX% XX% XXXX. generics oral our compared now XX% revenues to to XXXX. compared a generics of for in total in result, tangible for Also,
We performance. over diversification which bodes well for to financial expect consistent time, our grow
exceeded and course Let businesses creation, undoubtedly me metric of guidance exceptional financial deliver substantially their last pillars generation shared you grew every second to performance units we discuss now cash business third of financial XXXX. our record the of where was has and in value results over All year. with levels respective
timing million, XXXX revenue start well of to net very with down Products and biosimilars continue perform first million. and me strong in $XXX $XXX XXXX, we recorded was QX due of where QX. results, Generics Let in year-end $XX launched our orders. revenue million X% added to
grew in year grew of annual revenue adjusted AvKARE of growth. $XXX in all EBITDA our of quarterly QX $XXX is $XXX which million million XXXX net to ahead commercial as well as X% compared quarter, growth adjusted driven guidance. driven investments of products, Adjusted million why XX%, EBITDA and revenues our X we to customer Specialty brand exceeded key million level reflecting drive strong the prior R&D future expectations, average channels. of was by net QX while our across $XXX in EBITDA the QX by
QX operating driven as EPS cash prior million quarter. flow compared receivable. collections $XX both year perspective, we interest This of of $XXX $X.XX our well in to our as million of $X.XX expectations the related accounts in compares well of of and reflects growth benefits strong timing an was higher prior ahead underlying strength From the our negative quarter, mostly quarter generated XXXX, year costs. fourth to in by to business the the
Let X%. a Generics million me performance, added high-quality and XXXX X%. supply billion relevancy full strong XXXX, chain. our to demand X% market grew products, of growth. well to biosimilars due our net XXXX and up in $XXX billion, year record continues portfolio The Amneal's where net revenue $X.XXX revenue $X.X perform total launched of remaining level product of now or to of million Products discuss or $XXX grew the
key by customer and driven for revenue revenue driven products. across all and was branded was net commercial Specialty the X% by $XXX $XXX and year strong channels. grew year launches X product its million the AvKARE million XX%, net grew execution for new
and Full EBITDA X%, $XXX provided year $XXX the million. ahead November, in was guidance original guidance million million to well adjusted was million and XXXX grew as of $XXX which we million $XXX $XXX $XXX of as well -- our between
Our adjusted all year XXXX substantially growth was prior $X.XX our strong provided. operating growth favorable we as exceeded commercial X% spend in leverage, and again have R&D Nevertheless, Full performance adjusted interest EBITDA declined driven EPS expense our growth. offset of higher guidance by EPS expenses.
$XXX cash million $XX Operating XXXX flow compared was in to XXXX. million in
that December. It million our costs, in performance and of strong in XXXX is ahead operating also legal our well expectations to cash includes which million of for last we one XXXX ER $XX was benefited Our had approximately payment noting flow mostly end Opana collections worth XXXX, cash related $XXX remaining Opana the million, generation. ER bodes At of the the of well settlement future for only related $XX case. to from
strong XXXX turn another where of Let me expect now guidance we to year our growth.
expect line, total in reflecting net billion $X.XXX of all segments. On the $X.XXX company driven robust to high by we of billion, single-digit growth X growth revenue top our
$XXX over compared due compared one, single-digit XXXX to more XXXX. key in First, double to should in expect high growth X% dynamics. in to generics, Number million than X in biosimilars $XX million XXXX to we
and to products both add to approved Our substantial been continue drive should two, of million. launched X have new product and $XXX launches, oncology-focused payers patients. value over many Number which already
of which and million XXXX. do, quality and we're over expect addition, we of R&D add as the strength ], reliable generics advantages. always Amneal's Three, naloxone, In nature of to approval competitive supply potential on the $XX optimistic to in we [ persist the competitive be FDA chain could superb
in key this but in by Second, the Parkinson's have branded our conservatism. ensure of point not as products. our addition, to forward on compared any we to potential included expect double-digit we driven And the in revenues IPXXXX, specialty at proper approval low ONGENTYS growth to look franchise. business, X% XXXX, We
the Finally, continued XXXX, channels on across double-digit a AvKARE, new growth, XX% some broad-based line growth in top albeit all strength number from we launches. slowdown expect and of by driven
million in down between EPS single-digit the Moving adjusted we expect P&L, of offset our EBITDA pipeline. higher adjusted million, interest R&D investments by higher growth to and to the higher a high we partially $XXX numerous $X.XX, projects $XXX reflecting perspective, expect drive range continued by in adjusted EBITDA. an From $X.XX costs, driven and XXXX
we and expect expect generation cash and between year. to reflects expense. EBITDA, higher settlements legal interest operating $XXX capital collection we million accounts excluding a side, strong cash higher cash $XXX flow, a $XX the The million $XX million From receivable typical perspective, patterns On expenditure million.
to our the come from leverage and to value remarkably X.Xx XXXX pillar Finally, in make on of fourth XXXX. creation, deleveraging. X.Xx at progress down Net of continue we solid has end
For to that, by of XXXX, and Xx of below With turn $XXX then the thereafter. call over me to $XXX gross end between let we XXXX, the million Chirag. down expect and and pay below in to closer XXXX Xx net million leverage Xx soon reduced debt
